Frank Pensa, MD
Obstetrics & Gynecology · Providence, RINPI 1760405450
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.8% of the total across 27 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AbbVie at 29.0% of the total. Reporting peaked in 2019 at $320 and has fallen 93.7% since, to $20 in 2023.
Across 27 payments — averaging $19.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$149
- Pfizer$48
- Myovant Sciences Inc.$45
- Mylan Pharmaceuticals Inc.$38
- Astellas Pharma US Inc$34
- BD$29
- plus $172 from 9 others
What the payments were for
- Food & beverage$47893%
- Education$377%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 7 | $149 |
| Pfizer | 3 | $48 |
| Myovant Sciences Inc. | 2 | $45 |
| Mylan Pharmaceuticals Inc. | 2 | $38 |
| Astellas Pharma US Inc | 2 | $34 |
| BD | 2 | $29 |
| Covidien LP | 1 | $26 |
| Exeltis, USA Inc. | 1 | $22 |
| Evofem Biosciences, Inc. | 1 | $21 |
| Exact Sciences | 1 | $20 |
| AMAG Pharmaceuticals, Inc. | 1 | $20 |
| Merck | 1 | $18 |
| Bayer | 1 | $17 |
| Boston Scientific | 1 | $15 |
| Roche Diagnostics Corporation | 1 | $14 |
How this compares
$515 in reported general payments places this provider in the 60th percentile of 139 obstetrics & gynecology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 15 | $320 |
| Oxybutynin Chloride | 16 | $183 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 11 | $171 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Providence
- Warren HuberProvidence$50K
- Lisa BoyleProvidence$30K
- Renee EgerProvidence$24K
- Gary WhartonProvidence$22K
- Christine FoleyProvidence$21K
- Cara MathewsProvidence$21K
- Michael BeitleProvidence$9K
- Ogechukwu EzikeProvidence$7K
- Beata DizoglioProvidence$6K
- Michele GangeProvidence$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.